| pubmed-article:15246454 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0018220 | lld:lifeskim |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0449468 | lld:lifeskim |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0332189 | lld:lifeskim |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0441994 | lld:lifeskim |
| pubmed-article:15246454 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:15246454 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15246454 | pubmed:dateCreated | 2004-7-12 | lld:pubmed |
| pubmed-article:15246454 | pubmed:abstractText | Although a lower volume of prefrontal (PF) gray matter (GM) in patients with schizophrenia than in normal control subjects is a replicated finding, it is not yet clear whether this finding is present at the onset of illness. Clinical and imaging data suggest that the reduction in PF GM becomes apparent only some years following the onset of illness. To test this hypothesis, we used magnetic resonance imaging to study PF GM and sulcal cerebrospinal fluid (CSF) volumes in 81 schizophrenic patients. A Talairach-based tool was used for segmentation. Subjects included 44 healthy controls, 22 first-episode (FE), treatment-naïve patients with duration of illness of less than 1 year; 29 short-term chronic (SC) patients with durations of illness between 1.5 and 6 years; and 30 long-term chronic (LC) patients with duration of illness of more than 6 years. The data from healthy controls were used to calculate volume residuals in the patients, defined as deviations from the expected values given individual age and intracranial volume. The FE group did not show significant differences in GM or in CSF volumes compared with controls. However, both the SC and the LC patients showed the expected pattern of lower values for PF GM and an excess of PF sulcal CSF compared with controls. There were no significant differences between SC and LC patients in any of these measurements. There was a significant and inverse association between duration of illness and GM residuals. That association fit a nonlinear rather than a linear model, which was consistent with a decrease of GM volume during the first years following illness onset. No significant differences were found between those receiving atypical and typical antipsychotic drugs during the previous year. | lld:pubmed |
| pubmed-article:15246454 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15246454 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15246454 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15246454 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15246454 | pubmed:month | May | lld:pubmed |
| pubmed-article:15246454 | pubmed:issn | 0165-1781 | lld:pubmed |
| pubmed-article:15246454 | pubmed:author | pubmed-author:SanzJavierJ | lld:pubmed |
| pubmed-article:15246454 | pubmed:author | pubmed-author:MolinaVicente... | lld:pubmed |
| pubmed-article:15246454 | pubmed:author | pubmed-author:BenitoCarlosC | lld:pubmed |
| pubmed-article:15246454 | pubmed:author | pubmed-author:SarrameaFerna... | lld:pubmed |
| pubmed-article:15246454 | pubmed:author | pubmed-author:PalomoTomásT | lld:pubmed |
| pubmed-article:15246454 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15246454 | pubmed:day | 30 | lld:pubmed |
| pubmed-article:15246454 | pubmed:volume | 131 | lld:pubmed |
| pubmed-article:15246454 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15246454 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15246454 | pubmed:pagination | 45-56 | lld:pubmed |
| pubmed-article:15246454 | pubmed:dateRevised | 2008-4-17 | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:meshHeading | pubmed-meshheading:15246454... | lld:pubmed |
| pubmed-article:15246454 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15246454 | pubmed:articleTitle | Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. | lld:pubmed |
| pubmed-article:15246454 | pubmed:affiliation | Department of Psychiatry, Hospital Doce de Octubre, Edificio de Medicina Comunitaria, Avda de Córdoba, km 5.4, 28041 Madrid, Spain. vmolinarod@wanadoo.es | lld:pubmed |
| pubmed-article:15246454 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15246454 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15246454 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15246454 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15246454 | lld:pubmed |
